There are few data on the frequency of virological remission in African individuals after treatment with antiretroviral therapy (ART) in primary HIV infection (PHI).
We studied participants (n = 82) from South Africa and Uganda in Short Pulse Antiretroviral Treatment at HIV-1 Seroconversion, the first trial of treatment interruption in African individuals with PHI randomized to deferred ART or 48 weeks of immediate ART. All were female and infected with non-B HIV subtypes, mainly C. We measured HIV DNA in CD4+ T cells, CD4+ cell count, plasma viral load (pVL), cell-associated HIV RNA and T-cell activation and exhaustion. We explored associations with clinical progression and time to pVL rebound after treatment interruption (n = 22). Data were compared with non-African Short Pulse Antiretroviral Treatment at HIV-1 Seroconversion participants.
Pretherapy pVL and integrated HIV DNA were lower in Africans compared with non-Africans (median 4.16 vs. 4.72 log10 copies/ml and 3.07 vs. 3.61 log10 copies/million CD4+ T cells, respectively; P < 0.001). Pre-ART HIV DNA in Africans was associated with clinical progression (P = 0.001, HR per log10 copies/million CD4+ T cells increase (95% CI) 5.38 (1.95–14.79)) and time to pVL rebound (P = 0.034, HR per log10 copies/ml increase 4.33 (1.12–16.84)). After treatment interruption, Africans experienced longer duration of viral remission than non-Africans (P < 0.001; HR 3.90 (1.75–8.71). Five of 22 African participants (22.7%) maintained VL less than 400 copies/ml over a median of 188 weeks following treatment interruption.
We find evidence of greater probability of virological remission following treatment interruption among African participants, although we are unable to differentiate between sex, ethnicity and viral subtype. The finding warrants further investigation.
aPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, Oxford, UK
bHIV Prevention Research Unit, South African Medical Research Council, Durban, South Africa
cMedical Research Council/Uganda Virus Research Institute, Entebbe, Uganda
dWits Reproductive Health and HIV Institute of the University of the Witwatersrand, Johannesburg, South Africa
eMRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology
fInstitute for Global Health, University College London
gDivision of Medicine, Wright Fleming Institute, Imperial College, London
hThe Oxford Martin School
iOxford National Institute of Health Research Biomedical Research Centre, Oxford, UK.
Correspondence to John Frater, FRCP, PhD, Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Tel: +44 1865 271288; fax: +44 1865 281890; e-mail: email@example.com
Received 29 March, 2018
Accepted 13 September, 2018
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0